Koers Regen BioPharma, Inc. Other OTC
Aandelen
RGBP
US75886M1027
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 236K 219K | Omzet 2023 | 237K 220K | Marktkapitalisatie | 6,33 mln. 5,89 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | 2 mln. 1,86 mln. | Nettowinst (verlies) 2023 | 1 mln. 931K | EV/omzet 2022 | 144 x |
Nettoschuld 2022 | 1,22 mln. 1,14 mln. | Nettoschuld 2023 | 635K 591K | EV/omzet 2023 | 29,4 x |
K/w-verhouding 2022 |
13,7
x | K/w-verhouding 2023 |
6,24
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 99,99% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Koos
CEO | Chief Executive Officer | 64 | 24-04-12 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David Koos
CEO | Chief Executive Officer | 64 | 24-04-12 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,93% | 108 mld. | |
+7,02% | 23,46 mld. | |
-14,60% | 21,72 mld. | |
-7,05% | 18,64 mld. | |
-38,55% | 17,45 mld. | |
-8,83% | 17,19 mld. | |
+5,51% | 13,99 mld. | |
+37,49% | 12,53 mld. | |
+329,39% | 8,81 mld. |